^
    7d
    AREN0533: Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor (clinicaltrials.gov)
    P3, N=395, Completed, Children's Oncology Group | Trial completion date: Nov 2026 --> Mar 2026 | Active, not recruiting --> Completed
    Trial completion • Trial completion date
    |
    doxorubicin hydrochloride • cyclophosphamide • etoposide IV • dactinomycin • Marqibo (vincristine liposomal)
    3ms
    AREN0533: Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor (clinicaltrials.gov)
    P3, N=395, Active, not recruiting, Children's Oncology Group | Trial completion date: Mar 2026 --> Nov 2026
    Trial completion date
    |
    doxorubicin hydrochloride • cyclophosphamide • etoposide IV • dactinomycin • Marqibo (vincristine liposomal)
    4ms
    ECOG-ACRIN EA9152: Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1/2, N=40, Active, not recruiting, ECOG-ACRIN Cancer Research Group | N=74 --> 40 | Trial primary completion date: Dec 2025 --> Jul 2025
    Enrollment change • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Venclexta (venetoclax) • vincristine • Marqibo (vincristine liposomal)
    4ms
    Prospective, single-arm, multicenter clinical study of rituximab combined with cyclophosphamide, mitoxantrone liposomes, vincristine, and prednisone (R-CMOP) regimen in the treatment of previously untreated diffuse large B-cell lymphoma in patients aged 60 years or older or with underlying heart disease (ChiCTR2600117000)
    P=N/A, N=72, Not yet recruiting, The First Affiliated Hospital, College of Medicine, Zhejiang University; The First Affiliated Hospital of Zhejiang University School of Medicine
    New trial
    |
    Rituxan (rituximab) • cyclophosphamide • prednisone • Marqibo (vincristine liposomal) • Duoenda (mitoxantrone liposomal) • vindesine
    8ms
    AREN0533: Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor (clinicaltrials.gov)
    P3, N=395, Active, not recruiting, Children's Oncology Group | Trial completion date: Sep 2025 --> Mar 2026
    Trial completion date
    |
    doxorubicin hydrochloride • cyclophosphamide • etoposide IV • dactinomycin • Marqibo (vincristine liposomal)
    8ms
    Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy (clinicaltrials.gov)
    P1, N=29, Completed, Therapeutic Advances in Childhood Leukemia Consortium | Recruiting --> Completed | Trial completion date: Dec 2022 --> Dec 2024
    Trial completion • Trial completion date
    |
    methotrexate • Marqibo (vincristine liposomal)
    8ms
    Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies (clinicaltrials.gov)
    P1, N=11, Active, not recruiting, Medical College of Wisconsin | N=33 --> 11 | Trial completion date: May 2026 --> Oct 2027 | Trial primary completion date: May 2026 --> May 2025 | Recruiting --> Active, not recruiting
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    Rituxan (rituximab) • cyclophosphamide • etoposide IV • pegylated liposomal doxorubicin • vincristine • prednisone • Zynlonta (loncastuximab tesirine-lpyl) • Marqibo (vincristine liposomal)
    10ms
    NCI-2018-01198: Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia (clinicaltrials.gov)
    P2, N=42, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Aug 2026 --> Aug 2027 | Trial primary completion date: Aug 2025 --> Aug 2027
    Trial completion date • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Rituxan (rituximab) • bortezomib • cyclophosphamide • etoposide IV • clofarabine • Arzerra (ofatumumab) • Truxima (rituximab-abbs) • Marqibo (vincristine liposomal) • Hemady (dexamethasone tablets) • Neulasta (pegfilgrastim) • Neupogen (filgrastim)
    1year
    ECOG-ACRIN EA9152: Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1/2, N=74, Active, not recruiting, ECOG-ACRIN Cancer Research Group | Trial primary completion date: Dec 2028 --> Dec 2025
    Trial primary completion date • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Venclexta (venetoclax) • vincristine • Marqibo (vincristine liposomal)
    1year
    AREN0533: Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor (clinicaltrials.gov)
    P3, N=395, Active, not recruiting, Children's Oncology Group
    Trial completion date
    |
    doxorubicin hydrochloride • cyclophosphamide • etoposide IV • dactinomycin • Marqibo (vincristine liposomal)
    over1year
    Phase I/II clinical study of rituximab combined with cyclophosphamide, Mitoxantrone hydrochloride liposome, vincristine and prednisone in the treatment of newly diagnosed large B-cell lymphoma with bulky disease (ChiCTR2400093033)
    P4, N=51, Recruiting, The First Affiliated Hospital of Xi'an Jiaotong University; The First Affiliated Hospital of Xi'an Jiaotong University
    New P4 trial
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK positive
    |
    Rituxan (rituximab) • cyclophosphamide • prednisone • Marqibo (vincristine liposomal) • Duoenda (mitoxantrone liposomal)
    over1year
    ECOG-ACRIN EA9152: Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1/2, N=74, Active, not recruiting, ECOG-ACRIN Cancer Research Group | Recruiting --> Active, not recruiting
    Enrollment closed • Combination therapy • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    BCL2 expression
    |
    Venclexta (venetoclax) • vincristine • Marqibo (vincristine liposomal)